Literature DB >> 20470831

Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel.

Ravi S Kasinathan1, William M Morgan, Robert M Greenberg.   

Abstract

The ATP-binding cassette (ABC) superfamily of proteins comprises several ATP-dependent efflux pumps involved in transport of toxins and xenobiotics from cells. These transporters are essential components of normal physiology, and a subset is associated with development of multidrug resistance. P-glycoprotein (Pgp) and the multidrug resistance-associated proteins (MRPs) represent two classes of these multidrug resistance (MDR) transporters. MRP1 is one type of mammalian MRP, which preferentially transports anionic compounds and compounds detoxified by cellular enzymes such as glutathione-S-transferase. It also transports signaling molecules, including immunomodulators. In schistosomes, both Pgp and MRP substrates localize to the excretory system, a potentially attractive target for new antischistosomals. We have previously shown that expression of schistosome Pgp (SMDR2) is altered in worms exposed to praziquantel (PZQ), the current drug of choice against schistosomiasis, and is expressed at higher levels in worms from isolates with reduced PZQ susceptibility. We have also shown that PZQ interacts directly with SMDR2. Here, we examine the relationship between PZQ and SmMRP1, a Schistosoma mansoni homolog of mammalian MRP1. SmMRP1 RNA is differentially expressed in adult males and females, and levels increase transiently following exposure of adult worms to sub-lethal concentrations of PZQ. A corresponding, though delayed, increase in anti-MRP1-immunoreactive protein also occurs following exposure to PZQ. PZQ-insensitive juvenile worms express higher levels of both SmMRP1 and SMDR2 RNA than mature adults, consistent with the hypothesis that increases in levels of schistosome multidrug transporters may be involved in development or maintenance of reduced susceptibility to PZQ. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470831      PMCID: PMC2896741          DOI: 10.1016/j.molbiopara.2010.05.003

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  55 in total

1.  Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment.

Authors:  Livia Pica-Mattoccia; Donato Cioli
Journal:  Int J Parasitol       Date:  2004-03-29       Impact factor: 3.981

2.  Drug resistance mechanisms in helminths: is it survival of the fittest?

Authors:  Catherine E James; Amanda L Hudson; Mary W Davey
Journal:  Trends Parasitol       Date:  2009-06-21

Review 3.  Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters.

Authors:  E M Leslie; R G Deeley; S P Cole
Journal:  Toxicology       Date:  2001-10-05       Impact factor: 4.221

4.  Excretion of fluorescent substrates of mammalian multidrug resistance-associated protein (MRP) in the Schistosoma mansoni excretory system.

Authors:  H Sato; J R Kusel; J Thornhill
Journal:  Parasitology       Date:  2004-01       Impact factor: 3.234

5.  Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility.

Authors:  Shanta M Messerli; Ravi S Kasinathan; William Morgan; Stefani Spranger; Robert M Greenberg
Journal:  Mol Biochem Parasitol       Date:  2009-05-03       Impact factor: 1.759

6.  Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus.

Authors:  W J Blackhall; H Y Liu; M Xu; R K Prichard; R N Beech
Journal:  Mol Biochem Parasitol       Date:  1998-09-15       Impact factor: 1.759

7.  Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.

Authors:  M J Flens; M A Izquierdo; G L Scheffer; J M Fritz; C J Meijer; R J Scheper; G J Zaman
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

8.  Effect of praziquantel on the free living stages of Schistosoma mansoni.

Authors:  P Andrews
Journal:  Z Parasitenkd       Date:  1978-07-03

9.  P-glycoprotein interfering agents potentiate ivermectin susceptibility in ivermectin sensitive and resistant isolates of Teladorsagia circumcincta and Haemonchus contortus.

Authors:  D J Bartley; H McAllister; Y Bartley; J Dupuy; C Ménez; M Alvinerie; F Jackson; A Lespine
Journal:  Parasitology       Date:  2009-06-24       Impact factor: 3.234

Review 10.  The unacknowledged impact of chronic schistosomiasis.

Authors:  Charles H King; Madeline Dangerfield-Cha
Journal:  Chronic Illn       Date:  2008-03
View more
  23 in total

Review 1.  Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.

Authors:  Nuno Vale; Maria João Gouveia; Gabriel Rinaldi; Paul J Brindley; Fátima Gärtner; José M Correia da Costa
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Molecular and structural characteristics of multidrug resistance-associated protein 7 in Chinese liver fluke Clonorchis sinensis.

Authors:  Fuhong Dai; Won Gi Yoo; Ji-Yun Lee; Yanyan Lu; Jhang Ho Pak; Woon-Mok Sohn; Sung-Jong Hong
Journal:  Parasitol Res       Date:  2017-01-05       Impact factor: 2.289

Review 3.  Susceptibility or resistance of praziquantel in human schistosomiasis: a review.

Authors:  Wei Wang; Li Wang; You-Sheng Liang
Journal:  Parasitol Res       Date:  2012-10-07       Impact factor: 2.289

4.  Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro.

Authors:  Jarrett Hines-Kay; Pauline M Cupit; Melissa C Sanchez; George H Rosenberg; Ben Hanelt; Charles Cunningham
Journal:  Mol Biochem Parasitol       Date:  2012-09-27       Impact factor: 1.759

5.  A survey of schistosome protein domain types: insights into unique biological properties.

Authors:  Austin L Hughes; Robert Friedman
Journal:  Mol Biochem Parasitol       Date:  2011-02-18       Impact factor: 1.759

Review 6.  Pharmacology and potential physiological significance of schistosome multidrug resistance transporters.

Authors:  Ravi S Kasinathan; Robert M Greenberg
Journal:  Exp Parasitol       Date:  2011-03-21       Impact factor: 2.011

7.  Exogenous bone morphogenetic protein-7 reduces hepatic fibrosis in Schistosoma japonicum-infected mice via transforming growth factor-β/Smad signaling.

Authors:  Bo-Lin Chen; Jie Peng; Qing-Fu Li; Min Yang; Yuan Wang; Wei Chen
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

Review 8.  ABC multidrug transporters in schistosomes and other parasitic flatworms.

Authors:  Robert M Greenberg
Journal:  Parasitol Int       Date:  2013-03-06       Impact factor: 2.230

9.  New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.

Authors:  Stefano Guglielmo; Daniela Cortese; Francesca Vottero; Barbara Rolando; Valerie P Kommer; David L Williams; Roberta Fruttero; Alberto Gasco
Journal:  Eur J Med Chem       Date:  2014-07-03       Impact factor: 6.514

Review 10.  New approaches for understanding mechanisms of drug resistance in schistosomes.

Authors:  Robert M Greenberg
Journal:  Parasitology       Date:  2013-04-03       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.